{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:37:00Z","timestamp":1792100220346,"version":"4.4.0"},"reference-count":50,"publisher":"Japanese Society of Allergology","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,29]],"date-time":"2015-04-29T00:00:00Z","timestamp":1430265600000},"content-version":"vor","delay-in-days":3405,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2006]]},"DOI":"10.2332\/allergolint.55.9","type":"journal-article","created":{"date-parts":[[2006,3,23]],"date-time":"2006-03-23T00:58:18Z","timestamp":1143075498000},"page":"9-16","source":"Crossref","is-referenced-by-count":177,"title":["Toxic Epidermal Necrolysis and Stevens Johnson Syndrome: Our Current Understanding"],"prefix":"10.2332","volume":"55","author":[{"given":"Lars E","family":"French","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1154","reference":[{"key":"10.2332\/allergolint.55.9_bb0005","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.2332\/allergolint.55.9_bb0010","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archderm.1995.01690170041005","article-title":"Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes","volume":"131","author":"Assier","year":"1995","journal-title":"Arch. Derm."},{"key":"10.2332\/allergolint.55.9_bb0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0020","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archderm.138.8.1019","article-title":"Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study","volume":"138","author":"Auquier-Dunant","year":"2002","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption resembling scalding of the skin","volume":"68","author":"Lyell","year":"1956","journal-title":"Br. J. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0030","first-page":"97","article-title":"Lyell\u2019s toxic epidermal necrolysis : histologic aspects","volume":"26","author":"Achten","year":"1970","journal-title":"Arch. Belg. Dermatol. Syphiligr."},{"key":"10.2332\/allergolint.55.9_bb0035","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archderm.1990.01670250043005","article-title":"Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 19811985","volume":"126","author":"Roujeau","year":"1990","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0040","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0045","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN : a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0050","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/archderm.140.7.890","article-title":"Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States","volume":"140","author":"Trent","year":"2004","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0055","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/0190-9622(90)70333-D","article-title":"Toxic epidermal necrolysis(Lyell syndrome)","volume":"23","author":"Roujeau","year":"1990","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0060","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/archderm.1993.01680290135026","article-title":"Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with the acquired immunodeficiency syndrome in Germany","volume":"129","author":"Rzany","year":"1993","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0065","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0190-9622(99)70508-6","article-title":"Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital","volume":"40","author":"Duncan","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0070","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.2332\/allergolint.55.9_bb0075","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death ?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0080","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJM198109243051302","article-title":"Predisposition to phenytoin hepatotoxicity assessed in vitro","volume":"305","author":"Spielberg","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"10.2332\/allergolint.55.9_bb0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-105-2-179","article-title":"Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity","volume":"105","author":"Shear","year":"1986","journal-title":"Ann. Intern. Med."},{"key":"10.2332\/allergolint.55.9_bb0090","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/archderm.1995.01690170046006","article-title":"Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants","volume":"131","author":"Wolkenstein","year":"1995","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00008571-199508000-00011","article-title":"A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Wolkenstein","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.2332\/allergolint.55.9_bb0100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-0625.1995.tb00211.x","article-title":"Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"4","author":"Dietrich","year":"1995","journal-title":"Exp. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0105","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1001\/archderm.1987.01660330082014","article-title":"Genetic susceptibility to toxic epidermal ne- crolysis","volume":"123","author":"Roujeau","year":"1987","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0110","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.2332\/allergolint.55.9_bb0115","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.2332\/allergolint.55.9_bb0120","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/archderm.1986.01660160111029","article-title":"Lymphocyte subsets and Langerhans\u2019 cells in toxic epidermal ne- crolysis","volume":"122","author":"Merot","year":"1986","journal-title":"Report of a case. Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/archderm.1992.01680110060006","article-title":"Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases","volume":"128","author":"Villada","year":"1992","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0130","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1001\/archderm.1993.01680250078010","article-title":"Cutaneous T-cell recruitment in toxic epidermal necrolysis. Further evidence of CD8+ lymphocyte involvement","volume":"129","author":"Correia","year":"1993","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0135","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis : effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.2332\/allergolint.55.9_bb0140","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J. Invest. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0145","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.0022-202X.2004.23439.x","article-title":"Evaluation of the potential role of cytokines in toxic epidermal necrolysis","volume":"123","author":"Nassif","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0150","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br. J. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0155","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1523-1747.2000.00037.x","article-title":"Death receptors in cutaneous biology and disease","volume":"115","author":"Wehrli","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0160","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.2332\/allergolint.55.9_bb0165","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2230.2004.01635.x","article-title":"Toxic epidermal necrolysis treated with low-dose intravenous immunoglobulin: immunohistochemical study of Fas and Fas-ligand expression","volume":"29","author":"Ito","year":"2004","journal-title":"Clin. Exp. Dermatol"},{"key":"10.2332\/allergolint.55.9_bb0170","doi-asserted-by":"crossref","first-page":"16183","DOI":"10.1074\/jbc.M212188200","article-title":"Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions","volume":"278","author":"Viard-Leveugle","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.2332\/allergolint.55.9_bb0175","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0190-9622(08)80969-3","article-title":"Efficacy of cyclophosphamide in toxic epidermal necrolysis: clinical and pathophysiologic aspects","volume":"25","author":"Heng","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0180","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2230.1992.tb02163.x","article-title":"Toxic epidermal necrolysis treated with cyclosporin","volume":"17","author":"Hewitt","year":"1992","journal-title":"Clin. Exp. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0185","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J. Trauma."},{"key":"10.2332\/allergolint.55.9_bb0190","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1046\/j.1365-2133.1998.2576n.x","article-title":"Severe bullous drug reactions treated successfully with cyclophosphamide [letter]","volume":"139","author":"Trautmann","year":"1998","journal-title":"Br. J. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0195","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/archderm.1985.01660120074023","article-title":"Plasmapheresis in severe drug-induced toxic epidermal necrolysis","volume":"121","author":"Kamanbroo","year":"1985","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0200","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2133.1997.tb02175.x","article-title":"Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis-treatment with N-acetylcysteine","volume":"136","author":"Redondo","year":"1997","journal-title":"Br. J. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0205","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.2332\/allergolint.55.9_bb0210","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/archderm.139.1.39","article-title":"Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience","volume":"139","author":"Trent","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0220","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0225","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Derm. Venereol."},{"key":"10.2332\/allergolint.55.9_bb0230","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J. Burn. Care Rehabil."},{"key":"10.2332\/allergolint.55.9_bb0235","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis : does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J. Burn. Care Rehabil."},{"key":"10.2332\/allergolint.55.9_bb0240","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/j.1365-4632.2004.02048.x","article-title":"Prospective, non-comparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis","volume":"43","author":"Al-Mutairi","year":"2004","journal-title":"Int. J. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.2005.tb00704.x","article-title":"High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series","volume":"32","author":"Tan","year":"2005","journal-title":"J. Dermatol."},{"key":"10.2332\/allergolint.55.9_bb0250","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000070957","article-title":"Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study","volume":"207","author":"Prins","year":"2003","journal-title":"Dermatology"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1323893015309424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1323893015309424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T05:24:10Z","timestamp":1586755450000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893015309424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006]]}},"alternative-id":["S1323893015309424"],"URL":"https:\/\/doi.org\/10.2332\/allergolint.55.9","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2006]]}}}